全文获取类型
收费全文 | 7270篇 |
免费 | 442篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 106篇 |
妇产科学 | 129篇 |
基础医学 | 799篇 |
口腔科学 | 98篇 |
临床医学 | 902篇 |
内科学 | 1215篇 |
皮肤病学 | 82篇 |
神经病学 | 664篇 |
特种医学 | 440篇 |
外国民族医学 | 1篇 |
外科学 | 842篇 |
综合类 | 73篇 |
一般理论 | 8篇 |
预防医学 | 1026篇 |
眼科学 | 88篇 |
药学 | 528篇 |
中国医学 | 4篇 |
肿瘤学 | 660篇 |
出版年
2024年 | 2篇 |
2023年 | 32篇 |
2022年 | 28篇 |
2021年 | 140篇 |
2020年 | 76篇 |
2019年 | 149篇 |
2018年 | 193篇 |
2017年 | 127篇 |
2016年 | 130篇 |
2015年 | 173篇 |
2014年 | 225篇 |
2013年 | 459篇 |
2012年 | 594篇 |
2011年 | 627篇 |
2010年 | 349篇 |
2009年 | 341篇 |
2008年 | 541篇 |
2007年 | 527篇 |
2006年 | 498篇 |
2005年 | 486篇 |
2004年 | 505篇 |
2003年 | 538篇 |
2002年 | 447篇 |
2001年 | 52篇 |
2000年 | 35篇 |
1999年 | 68篇 |
1998年 | 82篇 |
1997年 | 49篇 |
1996年 | 42篇 |
1995年 | 40篇 |
1994年 | 30篇 |
1993年 | 31篇 |
1992年 | 12篇 |
1991年 | 14篇 |
1990年 | 6篇 |
1989年 | 2篇 |
1988年 | 8篇 |
1987年 | 6篇 |
1986年 | 2篇 |
1985年 | 7篇 |
1984年 | 10篇 |
1983年 | 7篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1930年 | 2篇 |
1926年 | 2篇 |
排序方式: 共有7720条查询结果,搜索用时 46 毫秒
81.
Martin E. Stryjewski Peter D. Potgieter Yu-Ping Li Steven L. Barriere Allan Churukian Jeff Kingsley G. Ralph Corey for the TD- Investigators Group 《Antimicrobial agents and chemotherapy》2012,56(11):5476-5483
TD-1792 is a first-in-class glycopeptide-cephalosporin heterodimer that exhibits bactericidal activity against Gram-positive pathogens. We conducted a randomized, double-blind, active-control, phase II trial in patients with complicated skin and skin structure infections caused by suspected or confirmed Gram-positive organisms. Patients 18 to 65 years old were randomized to receive 7 to 14 days of either TD-1792 (2 mg/kg of body weight intravenously [i.v.] every 24 h [q24h]) or vancomycin (1 g i.v. q12h, with dosage regimens adjusted per site-specific procedures). A total of 197 patients were randomized and received at least one dose of study medication. Rates of clinical success at the test-of-cure evaluation were similar in all analysis populations. Among 170 clinically evaluable patients, cure rates were 91.7% and 90.7% in the TD-1792 and vancomycin groups, respectively (95% confidence interval [CI] of −7.9 to 9.7 for the difference). In microbiologically evaluable patients with methicillin-resistant Staphylococcus aureus at baseline (n = 75), cure rates were 94.7% in the TD-1792 group and 91.9% in the vancomycin group. Microbiological eradication of Gram-positive pathogens (n = 126) was achieved in 93.7% and 92.1% of patients in the TD-1792 and vancomycin groups, respectively. Seven patients were discontinued from study medication due to an adverse event (AE): 2 and 5 in the TD-1792 and vancomycin groups, respectively. AEs were of similar types and severities between the two groups, other than pruritus, which was more common in patients who received vancomycin. No patients in the TD-1792 group experienced a serious AE. This study supports further clinical development of TD-1792 in patients with Gram-positive infection. 相似文献
82.
83.
84.
85.
87.
88.
89.
Jeff Cain Tom Campbell Heather Brennan Congdon Kim Hancock Megan Kaun Paul R. Lockman R. Lee Evans 《American journal of pharmaceutical education》2014,78(7)
It is time for colleges and schools of pharmacy to examine and confront the rising costs of pharmacy education and the increasing student loan debt borne by graduates. These phenomena likely result from a variety of complex factors. The academy should begin addressing these issues before pharmacy education becomes cost-prohibitive for future generations. This paper discusses some of the more salient drivers of cost and student debt load and offers suggestions that may help alleviate some of the financial pressures. 相似文献
90.
John R. Richards Jeff M. Lapoint Guillermo Burillo-Putze 《Clinical toxicology (Philadelphia, Pa.)》2018,56(1):15-24
Introduction: Cannabinoid hyperemesis syndrome is a clinical disorder that has become more prevalent with increasing use of cannabis and synthetic cannabinoids, and which is difficult to treat. Standard antiemetics commonly fail to alleviate the severe nausea and vomiting characteristic of the syndrome. Curiously, cannabinoid hyperemesis syndrome patients often report dramatic relief of symptoms with hot showers and baths, and topical capsaicin.Objectives: In this review, we detail the pharmacokinetics and pharmacodynamics of capsaicin and explore possible mechanisms for its beneficial effect, including activation of transient receptor potential vanilloid 1 and neurohumoral regulation. Putative mechanisms responsible for the benefit of hot water hydrotherapy are also investigated.Methods: An extensive search of PubMed, OpenGrey, and Google Scholar from inception to April 2017 was performed to identify known and theoretical thermoregulatory mechanisms associated with the endocannabinoid system. The searches resulted in 2417 articles. These articles were screened for relevant mechanisms behind capsaicin and heat activation having potential antiemetic effects. References from the selected articles were also hand-searched. A total of 137 articles were considered relevant and included.Capsaicin: Topical capsaicin is primarily used for treatment of neuropathic pain, but it has also been used successfully in some 20 cases of cannabinoid hyperemesis syndrome. The pharmacokinetics and pharmacodynamics of capsaicin as a transient receptor potential vanilloid 1 agonist may explain this effect. Topical capsaicin has a longer half-life than oral administration, thus its potential duration of benefit is longer.Capsaicin and transient receptor potential vanilloid 1: Topical capsaicin binds and activates the transient receptor potential vanilloid 1 receptor, triggering influx of calcium and sodium, as well as release of inflammatory neuropeptides leading to transient burning, stinging, and itching. This elicits a novel type of desensitization analgesia. Transient receptor potential vanilloid 1 receptors also respond to noxious stimuli, such as heat (>43?°C), acids (pH <6), pain, change in osmolarity, and endovanilloids. The action of topical capsaicin may mimic the effect of heat-activation of transient receptor potential vanilloid 1.Endocannabinoid system and transient receptor potential vanilloid 1: Cannabinoid hyperemesis syndrome may result from a derangement in the endocannabinoid system secondary to chronic exogenous stimulation. The relief of cannabinoid hyperemesis syndrome symptoms from heat and use of transient receptor potential vanilloid 1 agonists suggests a complex interrelation between the endocannabinoid system and transient receptor potential vanilloid 1.Temperature regulation: Hot water hydrotherapy is a mainstay of self-treatment for cannabinoid hyperemesis syndrome patients. This may be explained by heat-induced transient receptor potential vanilloid 1 activation.“Sensocrine” antiemetic effects: Transient receptor potential vanilloid 1 activation by heat or capsaicin results in modulation of tachykinins, somatostatin, pituitary adenylate-cyclase activating polypeptide, and calcitonin gene-related peptide as well as histaminergic, cholinergic, and serotonergic transmission. These downstream effects represent further possible explanations for transient receptor potential vanilloid 1-associated antiemesis.Conclusions: These complex interactions between the endocannabinoid systems and transient receptor potential vanilloid 1, in the setting of cannabinoid receptor desensitization, may yield important clues into the pathophysiology and treatment of cannabinoid hyperemesis syndrome. This knowledge can provide clinicians caring for these patients with additional treatment options that may reduce length of stay, avoid unnecessary imaging and laboratory testing, and decrease the use of potentially harmful medications such as opioids. 相似文献